What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...
Weight loss jabs could be used to treat Alzheimer’s disease after a study found the drug may slow cognitive decline. Liraglutide, sold under the brand name Saxenda, is prescribed to control blood ...
Semaglutide, the drug behind the blockbuster weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline in people with early-stage Alzheimer’s, according to two large new studies. The ...
Hosted on MSN
Alzheimer's breakthrough as weight loss jab is found to slow progression of memory robbing illness
If you or anyone you know are affected, go to www.alzheimers.org.uk/symptoms or contact their dementia support line on 0333 150 3456 A breakthrough weight loss jab ...
Researchers create the first sex-specific GLP-1 brain atlas, revealing why weight-loss drugs work differently in men and women.
A once-weekly amylin analog conferred up to 10.7% weight loss at 42 weeks among adults with overweight or obesity and featured a safety profile similar to placebo, according to topline results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results